Prolonged anticoagulation after discontinuation of argatroban and warfarin therapy in an obese patient with heparin-induced thrombocytopenia

Pharmacotherapy

Volumn 26, Issue 12 I, 2006, Pages 1806-1810

  Shapiro, Nancy L ^a   Durr, Emily A ^a   Krueger, Courtney D ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Activated partial thromboplastin time; aPTT; Argatroban; Heparin induced thrombocytopenia; International normalized ratio; INR; Obesity; Roux en Y gastric bypass surgery

Indexed keywords

ACETYLSALICYLIC ACID; ARGATROBAN; HEPARIN; HYDROCHLOROTHIAZIDE; HYDROCODONE; INSULIN; PARACETAMOL; POTASSIUM; POTASSIUM CHLORIDE; ROSIGLITAZONE; THROMBOPLASTIN; WARFARIN;

ADULT; AFRICAN AMERICAN; ANTICOAGULATION; ARTICLE; BLEEDING; CASE REPORT; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITAL DISCHARGE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LUNG EMBOLISM; MORBID OBESITY; OUTPATIENT CARE; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE COMPLICATION; RETREATMENT; ROUX Y ANASTOMOSIS; SIDE EFFECT; STOMACH BYPASS; THROMBOCYTE COUNT; TREATMENT DURATION;

ADULT; ANTICOAGULANTS; DRUG THERAPY, COMBINATION; FEMALE; GASTRIC BYPASS; HEPARIN; HUMANS; INTERNATIONAL NORMALIZED RATIO; OBESITY, MORBID; PARTIAL THROMBOPLASTIN TIME; PIPECOLIC ACIDS; PULMONARY EMBOLISM; THROMBOCYTOPENIA; TREATMENT OUTCOME; WARFARIN;

EID: 33845370074     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.12.1806     Document Type: Article

References (19)

1. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the seventh ACCP conference on cntithrombotic and thrombolytic therapy. Chest 2004;126:311-37S.
2. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis, frequency, avoidance and management. Drug Saf 1997;17:325-41.
3. Spinier SA, Dager W. Overview of heparin-induced thrombocytopenia. Am J Health-Syst Pharm 2003;60(suppl 5):5-11S.
4. Kelton JG. The pathophysiology of heparin-induced thrombocytopenia: biological basis for treatment. Chest 2005;127:9-20S.
5. Bartholomew JR. Transition to an oral anticoagulant in patient with heparin-induced thrombocytopenia. Chest 2005;127:27-34S.
6. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502-7.
7. Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999;106:629-35.
8. Hassell K. The management of patients with heparin-induced thrombocytopenia who require anticoagulant therapy. Chest 2005;127:1-8S.
9. Ansell J. New anticoagulants and their potential impact on the treatment of thromboembolic disease. Curr Hematol Rep 2004;3:357-62.
10. Davidson BL. Preparing for the new anticoagulants. J Thromb Thrombolysis 2003;16:49-54.
11. Turpie AG. Fondaparinux: a factor Xa inhibitor for antithrombotic therapy. Expert Opin Pharmacother 2004;5:1373-84.
12. GlaxoSmithKline. Argatroban product information. Research Triangle Park, NC; July 2005.
13. Frenkel EP, Shen YM, Haley BB. The direct thrombin inhibitors: their role and use for rational anticoagulation. Hematol Oncol Clin North Am 2005;19(1):119-45.
14. Monreal M, Costa J, Salva P. Pharmacological properties of hirudin and its derivatives. Drugs Aging 1996;8:171S-82.
15. Abir F, Bell R. Assessment and management of the obese patient. Crit Care Med 2004;32:87-91.
16. Kubiak DW, Szumita PM, Fanikos JR. Extensive prolongation of aPTT with argatroban in an elderly patient with improving renal function, normal hepatic enzymes, and metastatic lung cancer. Ann Pharmacother 2005;39:1119-23.
17. Spinler SA, Dager W. Comment: extensive prolongation of aPTT with argatroban in an elderly patient with improving renal function, normal hepatic enzymes, and metastatic lung cancer. Ann Pharmacother 2005;39:1955-6.
18. Kearon C, Johnston M, Moffat K, McGinnis J, Ginsberg JS. Effect of warfarin on activated partial thromboplastin time in patients receiving heparin. Arch Intern Med 1998;158:1140-3.
19. Reichert MG, MacGregor DA, Kincaid EH, Dolinski SY. Excessive argatroban anticoagulation for heparin-induced thrombocytopenia. Ann Pharmacother 2003;37:652-4.